TransMedics Group, Inc. (TMDX) trades at a trailing P/E of 19.7, forward P/E of 47.7. Trailing earnings yield is 5.09%, forward earnings yield 2.10%. PEG 0.05 (Peter Lynch undervalued ≤1.0). Graham Number is $41.59.
Criteria proven by this page:
Overall SharesGrow Score: 77/100 with 4/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -13.5 | 0.00 | 8.35 | 52.14 | - |
| 2017 | -15.5 | 1.17 | -1.92 | 42.13 | - |
| 2018 | -18.1 | 1.24 | -89.19 | 33.06 | - |
| 2019 | -8.0 | -0.09 | 4.94 | 11.44 | - |
| 2020 | -17.1 | 0.34 | 4.73 | 19.17 | - |
| 2021 | -12.0 | -0.32 | 7.80 | 17.49 | - |
| 2022 | -50.4 | 2.18 | 9.74 | 19.52 | - |
| 2023 | -102.5 | 2.74 | 18.71 | 10.62 | - |
| 2024 | 58.4 | -0.24 | 9.06 | 4.69 | - |
| 2025 | 21.7 | 0.05 | 8.74 | 6.83 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-1.66 | $6.21M | $-24.07M | -387.6% |
| 2017 | $-1.44 | $7.69M | $-20.82M | -271% |
| 2018 | $-1.23 | $13.02M | $-23.76M | -182.5% |
| 2019 | $-2.36 | $23.6M | $-33.55M | -142.1% |
| 2020 | $-1.16 | $25.64M | $-28.75M | -112.1% |
| 2021 | $-1.60 | $30.26M | $-44.22M | -146.1% |
| 2022 | $-1.23 | $93.46M | $-36.23M | -38.8% |
| 2023 | $-0.77 | $241.62M | $-25.03M | -10.4% |
| 2024 | $1.01 | $441.54M | $35.46M | 8% |
| 2025 | $4.87 | $605.49M | $190.29M | 31.4% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $2.50 | $2.10 – $2.89 | $739.34M | $735.89M – $744.39M | 7 |
| 2027 | $3.68 | $3.30 – $4.02 | $879.63M | $874.95M – $886.43M | 7 |
| 2028 | $4.87 | $4.57 – $5.54 | $1.03B | $1.02B – $1.03B | 4 |
| 2029 | $5.81 | $5.74 – $5.91 | $1.21B | $1.2B – $1.23B | 2 |
